Gujarat Cancer and Research Institute Treats over 4,300 patients in 4 years

Published On 2025-08-04 12:24 GMT   |   Update On 2025-08-04 12:24 GMT
Advertisement

Gujarat Cancer and Research Institute Treats over 4,300 patients in 4 years, urges early screening

The Gujarat Cancer and Research Institute (GCRI) in Ahmedabad has treated 4,397 cancer patients between 2020 and 2024, reinforcing the state's emergence as a national hub for advanced lung cancer treatment.

Of these, 3,256 patients benefited from the PMJAY-MA health scheme, underscoring the state’s commitment to affordable, high-quality cancer care.

Speaking on World Lung Cancer Day, GCRI officials urged the public to prioritise early screening and tobacco cessation, stressing that over 40 per cent of cases in India are diagnosed at late stages, significantly reducing survival chances, news agency IANS reported.

GCRI Director Dr. Shashank Pandya emphasised, “Awareness is our greatest defence. Early detection, quitting tobacco, and timely care can save lives.”

Advertisement

The annual number of patients seeking treatment at GCRI has seen a steady rise: 700 in 2020, 813 in 2021, 865 in 2022, 933 in 2023 and 1,086 in 2024. Among the 4,397 patients treated, 3,597 were men, 799 were women, and one child, with 1,426 patients coming from other Indian states—further validating Gujarat’s growing reputation in cancer care.

For more information, click on the link below:

Gujarat Cancer and Research Institute Treats over 4,300 patients in 4 years, urges early screening

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News